Updated 2/23/26
If you’re a dividend investor who prefers consistency over flash, Quest Diagnostics might be a name worth knowing. It’s carved out a dependable niche in the healthcare world—quietly producing steady results and treating its shareholders well in the process.
Quest operates one of the largest diagnostic testing networks in the U.S. It’s deeply embedded in the healthcare system, offering everything from routine blood tests to complex genetic screenings. This isn’t a glamorous business, but it’s essential—and that kind of necessity tends to lead to reliability. For income-focused investors, that reliability can be pretty appealing.
Let’s take a closer look at what’s happening with Quest now, and how its dividend measures up for investors who prioritize income with a side of safety.
Recent Events
Quest has continued to build on the momentum it established heading into 2025. Revenue for the trailing twelve months crossed $11 billion, a meaningful milestone that reflects both organic volume growth and the contribution from recent acquisitions. Net income came in at $988 million, with EPS of $8.74, demonstrating that the company isn’t just growing the top line—it’s converting revenue into real profits. Operating cash flow reached $1.886 billion over the same period, underscoring the strength of the underlying cash generation engine.
Shares have responded accordingly. DGX is trading near $207, not far off its 52-week high of $213.20 and well above the low of $157.20 set earlier in the cycle. That’s a significant run, and it reflects the market’s growing appreciation for the durability of Quest’s business model in a normalized post-pandemic environment. For income investors considering a new position, the entry point warrants careful thought—but the fundamental picture remains compelling.
Key Dividend Metrics
📈 Forward Yield: 1.58%
💰 Annual Dividend: $3.44 per share
🔁 5-Year Average Yield: ~1.89%
📊 Payout Ratio: 36.00%
📆 Most Recent Dividend Paid: $0.80 per share (January 13, 2026)
📈 Dividend Growth Streak: Over 14 years
🔐 Dividend Safety: Strongly supported by $1.26 billion in free cash flow
Dividend Overview
At first glance, Quest’s dividend yield of 1.58% might not turn heads—especially with shares trading near $207. But this is where a steady hand counts more than a headline number. The yield looks modest not because the dividend is weak, but because the stock price has appreciated considerably, which is actually a good problem for long-term shareholders to have.
Quest raised its quarterly dividend to $0.80 per share beginning with the April 2025 payment, bringing the annual payout to $3.44. That increase from the prior $0.75 quarterly rate represents a 6.7% hike—consistent with the kind of deliberate, reliable growth that income investors have come to expect from this company. The payout ratio sits at a comfortable 36%, leaving ample room for continued increases even if earnings growth moderates.
What makes the dividend especially attractive is its consistency. Free cash flow for the trailing twelve months came in at approximately $1.26 billion, dwarfing the annual dividend obligation and making the payout one of the better-covered in the healthcare services space. Operating cash flow of $1.886 billion provides an even wider margin of safety.
Dividend Growth and Safety
Dividend safety is often where income stories fall apart, but not here. Quest’s dividend is well-protected by a business model built on recurring, essential testing volumes and long-term contracts with payers, employers, and health systems. The company has increased its dividend every year for more than 14 consecutive years, and nothing in the current financial picture suggests that streak is in jeopardy.
Growth has been steady—typically in the 6 to 7 percent annual range. The most recent increase, from $0.75 to $0.80 per quarter, fits squarely in that pattern. It’s not the kind of dividend acceleration that makes headlines, but it’s meaningful. At that pace, purchasing power is meaningfully preserved over a full market cycle.
With a payout ratio of just 36% against EPS of $8.74, Quest has substantial flexibility. Free cash flow of $1.26 billion provides a real-world backstop well beyond what the dividend requires. Even in a scenario where earnings pull back modestly, the dividend would remain well-covered. The risk here is not a cut—it’s a slower rate of growth, which is a very different kind of problem for a long-term income investor to manage.
Analyst Ratings
Analyst coverage of DGX reflects the tension that often surrounds a high-quality compounder trading near its 52-week highs. With shares approaching $207 and a 52-week high of $213.20, the valuation debate has become the central focus of most institutional research. At current prices, even analysts who are constructive on the long-term thesis are tempering their near-term enthusiasm.
The company’s financial performance has been difficult to argue with. Revenue crossing $11 billion, operating cash flow near $1.9 billion, and EPS of $8.74 all represent a business executing at a high level. Those results have driven the stock meaningfully higher over the past year, which naturally compresses the forward upside for new buyers. Analysts who had price targets in the $185 to $195 range earlier in 2025 have seen those levels passed, and revisions will be needed to reflect the current trajectory.
The broader analyst community has generally maintained a moderate buy or hold stance on DGX, with the constructive thesis centered on Quest’s pricing power, its expanding role in employer wellness testing, and ongoing efficiency gains in its lab network. The cautious counterpoint focuses on reimbursement rate risk and the stock’s valuation premium relative to historical norms. With a P/E of 23.73 and a price-to-book of 3.18, the stock is priced for continued execution—which, given Quest’s track record, is a reasonable but not riskless expectation.
For income investors, the analyst debate matters less than the fundamentals, and those remain firmly in Quest’s favor. The dividend is growing, cash flow is strong, and the balance sheet is manageable. Whether the stock is priced to deliver 5% or 12% total return over the next year is a valuation question—dividend sustainability is a separate and far more comfortable conversation.
Earning Report Summary
Quest’s most recently reported results paint the picture of a business operating with impressive consistency. Revenue for the trailing twelve months came in at $11.03 billion, a figure that would have seemed aspirational just a few years ago and now reflects a company that has successfully diversified beyond pandemic-driven testing volumes into a broader, more durable revenue base. Net income of $988 million translated to EPS of $8.74—a solid result that comfortably supports both the dividend and ongoing reinvestment in the business.
Operating cash flow of $1.886 billion is the number that stands out most for dividend investors. That’s a meaningful increase from prior periods and reflects not just top-line growth but genuine operational discipline. Capital expenditures consumed roughly $629 million of that, leaving free cash flow of approximately $1.26 billion. With annual dividend obligations well below that figure, the payout is among the most comfortably covered in the diagnostics sector.
Profit margins came in at 8.99%, which reflects the cost structure of running a large-scale laboratory network while continuing to invest in technology and infrastructure. Return on equity of 14.75% and return on assets of 6.41% round out a balance sheet picture that speaks to disciplined capital allocation rather than aggressive financial engineering. Quest isn’t generating flashy returns on equity by loading up on debt—it’s earning them through operational performance.
The company’s guidance issued earlier for full-year 2025 revenue of $10.7 to $10.85 billion now looks to have been conservative, suggesting that management’s execution has exceeded even its own expectations. That pattern of under-promising and over-delivering is exactly what dividend investors want to see from the companies they hold for the long run.
Financial Health and Stability
From a balance sheet perspective, Quest is in solid shape. The company carries debt consistent with the capital-intensive nature of its laboratory network, but the interest coverage picture is comfortable given operating cash flow approaching $1.9 billion. There are no signs of financial stress, and the company has demonstrated the ability to service its obligations while still returning meaningful capital to shareholders through both dividends and repurchases.
Return on equity of 14.75% and return on assets of 6.41% reflect a business earning real returns on the capital it employs, not just leveraging up to juice metrics. Book value per share of $65.18 gives some context to the current price-to-book of 3.18—investors are paying a premium, but one that is grounded in Quest’s consistent cash generation and dominant market position. The company’s active share repurchase program has also been a steady contributor to per-share value growth, complementing the dividend in delivering total returns to long-term holders.
Valuation and Stock Performance
Valuation is a more nuanced conversation at $207 than it was at the levels DGX traded just a year ago. The P/E ratio of 23.73 represents a meaningful premium to where the stock has historically traded, and a price-to-book of 3.18 reflects the confidence the market has developed in Quest’s ability to generate durable free cash flow. For a business with a beta of just 0.68 and a dividend streak exceeding 14 years, that kind of multiple isn’t unreasonable—but it does imply that continued execution is already priced in.
The 52-week range of $157.20 to $213.20 tells the story of a stock that has made a decisive move higher over the past year. Shares are currently trading near the top of that range at $207.43, which narrows the margin of safety for new buyers compared to entry points available even six months ago. For long-term income investors already in the position, this has been a rewarding run. For those considering initiating, patience for a modest pullback toward the $190 to $195 range would improve the yield on cost and reduce downside risk. At current prices, the forward yield of 1.58% is below Quest’s five-year average yield of approximately 1.89%—a signal that the stock is trading at the richer end of its historical valuation band.
Risks and Considerations
No dividend is without risk, and DGX has its share of potential headwinds. The most persistent concern is reimbursement pricing. A significant portion of Quest’s revenue flows through private insurers and government programs like Medicare and Medicaid. Any sustained pressure on reimbursement rates—whether from policy changes or payer negotiations—could compress margins in ways that are difficult to offset purely through volume growth or cost cutting.
Competition remains a structural reality. Quest and LabCorp together dominate the national testing market, but regional labs, hospital-based systems, and the continued expansion of point-of-care and at-home testing options create friction at the margins. These alternatives have not materially disrupted Quest’s core business, but they are worth monitoring over a multi-year horizon.
On the valuation front, a stock trading near its 52-week highs with a P/E above 23 carries more downside risk in a market correction than one priced more conservatively. The low beta of 0.68 provides some cushion relative to broad market volatility, but it doesn’t eliminate the risk of a valuation re-rating if earnings growth disappoints or interest rates shift in ways that make high-yield alternatives more competitive with dividend payers in Quest’s yield range.
From a pure dividend standpoint, the risk of a cut is low. The 36% payout ratio and $1.26 billion in free cash flow give the company substantial room to maneuver. The more realistic scenario in a stress case is slower dividend growth—which, while less exciting, is a far more manageable outcome for a long-term income investor than a reduction.
Final Thoughts
Quest Diagnostics isn’t a stock that gets people excited—and that’s kind of the point. For dividend investors, it’s the kind of company that quietly goes about its business, steadily growing earnings and sharing those profits with shareholders. With revenue now exceeding $11 billion, free cash flow above $1.26 billion, and a dividend that has grown for more than 14 consecutive years, the fundamental case for DGX remains intact.
The yield of 1.58% won’t satisfy income investors who need their portfolio to generate heavy current cash flow. But for those in accumulation mode who value dividend growth, safety, and a low-volatility business model, Quest offers a combination that’s genuinely hard to replicate. The most recent raise—from $0.75 to $0.80 per quarter—confirms that management remains committed to growing the payout, not just maintaining it.
The stock’s run toward $207 does require a candid acknowledgment that today’s entry point is less attractive than it was a year ago. Patient investors who can wait for a better price will be rewarded with a more favorable yield on cost and a wider margin of safety. But for those already holding, Quest continues to be exactly what it’s always been: a steady, essential business that earns its place in a long-term income portfolio one reliable dividend check at a time.